Medical Technology Advances Cited By HIAA/BCBSA As Driver In Health Spending Increases Over Next 5 Years

March 2001
Insurance Advocate;03/17/2001, Vol. 112 Issue 11, p30
Focuses on the report `The Impact of Medical Technology on Future Health Care Costs' released by the Health Insurance Association of America and the Blue Cross Blue Shield Association. How the cost of medical technology would affect the cost of medical care in the United States; Cost-effectiveness of medical technologies; Determinants of medical technology cost.


Related Articles

  • Medical technology as a key driver of rising health expenditure: disentangling the relationship. Sorenson, Corinna; Drummond, Michael; Khan, Beena Bhuiyan // ClinicoEconomics & Outcomes Research;May2013, Vol. 5, p223 

    Health care spending has risen steadily in most countries, becoming a concern for decision-makers worldwide. Commentators often point to new medical technology as the key driver for burgeoning expenditures. This paper critically appraises this conjecture, based on an analysis of the existing...

  • Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the Room. Eckermann, Simon; Pekarsky, Brita // PharmacoEconomics;Apr2014, Vol. 32 Issue 4, p319 

    In current literature, displaced services have been suggested to provide a basis for determining a threshold value for the effects of a new technology as part of a reimbursement process when budgets are fixed. We critically examine the conditions under which displaced services would represent an...

  • Getting To 'Smart' Health Care. Clancy, Carolyn M. // Health Affairs;2006 Web Exclusives, Vol. 25, pw589 

    As the United States struggles with improving the return on its sizable health care investment and consumers become increasingly involved in health care decisions, interest in comparative effectiveness will rise because of its relevance to value, personalized health care, quality, and cost...

  • Medicare and Cost-Effectiveness Analysis. Neumann, Peter J.; Rosen, Allison B.; Weinstein, Milton C. // New England Journal of Medicine;10/6/2005, Vol. 353 Issue 14, p1516 

    Discusses the role of cost-effectiveness analysis in the Medicare program of the United States. Discussion of 1989, when Medicare formally proposed the use of cost-effectiveness as one of several criteria for covering new medical technologies; Explanation of the reasons for Medicare's resistance...

  • QALYs: are they helpful to decision makers? McGregor, Maurice; Caro, J. Jaime // PharmacoEconomics;2006, Vol. 24 Issue 10, p947 

    The QALY is the product of life expectancy (estimated in years) and its quality over that time (estimated in utilities or QOL units). It theoretically enables direct comparison of the costs of obtaining different health outcomes through cost utility analysis (CUA). In this review, we argue that,...

  • Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration. Mitchell, Paul; Annemans, Lieven; White, Richard; Gallagher, Meghan; Thomas, Simu // PharmacoEconomics;2011, Vol. 29 Issue 2, p107 

    Age-related macular degeneration (AMD) is a leading cause of blindness in people aged ≥50 years. Wet AMD in particular has a major impact on patient quality of life and imposes substantial burdens on healthcare systems. This systematic review examined the cost-effectiveness data for...

  • The Analysis of Multinational Cost-Effectiveness Data for Reimbursement Decisions. Andrea Manca; Sculpher, Mark J.; Goeree, Ron // PharmacoEconomics;2010, Vol. 28 Issue 12, p1079 

    Evidence produced by multinational trial-based cost-effectiveness studies is often used to inform decisions concerning the adoption of new healthcare technologies. A key issue relating to the use of this type of evidence is the extent to which trial-wide economic results are applicable to every...

  • Presenting Evidence and Summary Measures to Best Inform Societal Decisions When Comparing Multiple Strategies. Eckermann, Simon; Willan, Andrew R. // PharmacoEconomics;2011, Vol. 29 Issue 7, p563 

    Multiple strategy comparisons in health technology assessment (HTA) are becoming increasingly important, with multiple alternative therapeutic actions, combinations of therapies and diagnostic and genetic testing alternatives. Comparison under uncertainty of incremental cost, effects and cost...

  • Accounting for the Drug Life Cycle and Future Drug Prices in Cost-Effectiveness Analysis. Hoyle, Martin // PharmacoEconomics;2011, Vol. 29 Issue 1, p1 

    Economic evaluations of health technologies typically assume constant real drug prices andmodel only the cohort of patients currently eligible for treatment. It has recently been suggested that, in the UK, we should assume that real drug prices decrease at 4%per annum and, in New Zealand, that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics